More Evidence Linking Januvia to Heart Failure Found
An analysis of patient-level data has found additional evidence that the type 2 diabetes treatment Januvia (sitaglitptin) poses an increased risk of new heart failure (HF) hospitalization.
About the Januvia Study
According to Medscape, the analysis looked at patient-level data from U.S. insurance records. In total, the review included information from 7,600 patients who were followed for a median of 1.4 years.
While the study found no sign of increased risk of all-cause hospitalization or death, data did show that diabetic HF patients initially treated with metformin or a sulfylure were 84 percent more likely to experience a new HF hospitalization after beginning treatment with Januvia.
Authors of the study labeled the increased HF risk as “likely clinically relevant,” stating the risk may affect whether Januvia will be considered as an add-on therapy for patients with HF and diabetes that respond poorly to other approved medications.
Concerns Cited in Similar Diabetes Drugs
Similar concerns have been cited in other DPP-4 inhibitors, including Onglyza (saxagliptin) and Nesina (alogliptin).
In a randomized trial, SAVOR-TIMI 53, Onglyza resulted in a 27 percent increased risk of HF hospitalizations in 16,492 patients diagnosed with diabetes and a history of cardiovascular events.
In the EXAMINE trial, 5,380 patients taking Nesina were found to be at an increased risk of heart failure.
Other adverse events observed in patients taking DDP-4 inhibitors include:
- Renal failure
- Interstitial lung disease
- Upper respiratory tract infection
- Pancreatic carcinoma